- Citations, last 5 years
- 0
- Works, last 5 years
- 0
- h-index
- 28
- Scientists listed
- 0
- Grants since 2016
- 15
Grants received
2025–2027 · research · R44
Development of a continuous microbial fermentation system using reduced genome E. coli that undergo programmed autolysis and generate nuclease post-production for the manufacture of biopharmaceuticals
David A Frisch · Scarab Genomics (United States) · funded by National Institutes of Health
2024–2027 · research · R44
An improved low-endotoxin Clean Genome E. coli strain for production of biological products
Frederick R Blattner · Scarab Genomics (United States) · funded by National Institutes of Health
2024–2027 · research · R44
An improved low-endotoxin Clean Genome E. coli strain for production of biological products
Frederick R Blattner · Scarab Genomics (United States) · funded by National Institutes of Health
2020–2024 · research · R44
Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture
Frederick R Blattner · Scarab Genomics (United States) · funded by National Institutes of Health
2020–2023 · research · R44
Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture
Frederick R Blattner · Scarab Genomics (United States) · funded by National Institutes of Health
2020–2023 · research · R44
Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture
Frederick R Blattner · Scarab Genomics (United States) · funded by National Institutes of Health
2019 · research · R44
Lysis-free extraction of biopharmaceuticals from the periplasm of Clean Genome E. coli
Frederick R Blattner · Scarab Genomics (United States) · funded by National Institutes of Health
2019–2021 · research · R44
Lysis-free extraction of biopharmaceuticals from the periplasm of Clean Genome E. coli
Frederick R Blattner · Scarab Genomics (United States) · funded by National Institutes of Health
2019–2022 · research · R44
Lysis-free extraction of biopharmaceuticals from the periplasm of Clean Genome E. coli
Frederick R Blattner · Scarab Genomics (United States) · funded by National Institutes of Health
2016–2020 · research · R44
Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics’ reduced genome E. coli strains
Frederick R Blattner · Scarab Genomics (United States) · funded by National Institutes of Health
2016–2017 · research · R44
Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics’ reduced genome E. coli strains
Frederick R Blattner · Scarab Genomics (United States) · funded by National Institutes of Health
2016–2019 · research · R44
Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics’ reduced genome E. coli strains
Frederick R Blattner · Scarab Genomics (United States) · funded by National Institutes of Health
2012–2022 · research · R44
Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain
Frederick R Blattner · Scarab Genomics (United States) · funded by National Institutes of Health
2012–2023 · research · R44
Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain
Frederick R Blattner · Scarab Genomics (United States) · funded by National Institutes of Health
2012–2022 · research · R44
Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain
Frederick R Blattner · Scarab Genomics (United States) · funded by National Institutes of Health
